NDC 0074-2100 – Skyrizi
Risankizumab 150 mg/mL · Injection · Subcutaneous
Product NDC0074-2100
Product details
- Brand name
- Skyrizi
- Generic name
- Risankizumab-rzaa
- Labeler
- AbbVie Inc.
- Dosage form
- Injection
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761105
- Marketed since
- April 26, 2021
- Listing expires
- December 31, 2027
- Pharmacologic class
- Interleukin-23 Antagonist
Active ingredients
- Risankizumab 150 mg/mL
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 0074-2100-01 | 1 SYRINGE in 1 CARTON (0074-2100-01) / 1 mL in 1 SYRINGE | Apr 26, 2021 |
| 0074-2100-70 sample | 1 SYRINGE in 1 CARTON (0074-2100-70) / 1 mL in 1 SYRINGE | Apr 26, 2021 |
Other Skyrizi products
- 0074-1050 Risankizumab 150 mg/mL · Injection · AbbVie Inc.
- 0074-5015 Risankizumab 600 mg/10mL · Injection · AbbVie Inc.
- 0074-8300 Risankizumab 180 mg/1.2mL · Injection · AbbVie Inc.
- 0074-8350 Risankizumab 180 mg/1.2mL · Injection · AbbVie Inc.
- 0074-1065 · Kit · AbbVie Inc.
- 0074-1070 · Kit · AbbVie Inc.
- 0074-4059 Risankizumab 55 mg/.37mL · Injection, Solution · AbbVie Inc.
- 0074-7040 · Kit · AbbVie Inc.
- 0074-7042 · Kit · AbbVie Inc.